ARQ 087

Drug Profile

ARQ 087

Alternative Names: ARQ-087

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator ArQule
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma
  • Phase I Solid tumours

Most Recent Events

  • 03 Jun 2017 Updated efficacy data from a phase I/II trial in Cholangiocarcinoma released by ArQule
  • 03 May 2017 Arqule plans a registrational phase III trial for Cholangiocarcinoma (Treatment-experienced, Second-line therapy or greater)
  • 09 Mar 2017 ArQule has patent protection for ARQ 087 in the European Union, Australia, China, Japan, Israel, Taiwan, the Philippines, Mexico, Macau and South Africa (ArQule's form 10-K, filed in March 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top